Health-related quality of life in relapsed/refractory multiple myeloma treated with melflufen and dexamethasone: analyses from the phase III OCEAN study
Jazyk angličtina Země Itálie Médium electronic
Typ dokumentu klinické zkoušky, fáze III, multicentrická studie, práce podpořená grantem, časopisecké články
PubMed
38426292
PubMed Central
PMC11215352
DOI
10.3324/haematol.2023.284635
Knihovny.cz E-zdroje
- MeSH
- chemorezistence MeSH
- dexamethason * terapeutické užití aplikace a dávkování MeSH
- fenylalanin terapeutické užití analogy a deriváty MeSH
- kvalita života * MeSH
- lidé středního věku MeSH
- lidé MeSH
- lokální recidiva nádoru farmakoterapie MeSH
- mnohočetný myelom * farmakoterapie MeSH
- protokoly protinádorové kombinované chemoterapie * terapeutické užití škodlivé účinky MeSH
- recidiva MeSH
- senioři MeSH
- výsledek terapie MeSH
- Check Tag
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- klinické zkoušky, fáze III MeSH
- multicentrická studie MeSH
- práce podpořená grantem MeSH
- Názvy látek
- dexamethason * MeSH
- fenylalanin MeSH
Bone Marrow Transplantation Unit and Department of Hematology Evangelismos Hospital Athens Greece
Dana Farber Cancer Institute Boston MA
Department of Hemato Oncology and Bone Marrow Transplantation Medical University of Lublin
Department of Hemato Oncology University Hospital Ostrava Ostrava Czech Republic
Department of Internal Medicine and Haematology Semmelweis University Budapest Hungary
Erasmus MC Cancer Institute Rotterdam
Hospital Clínico Universitario de Salamanca IBSAL CIC Salamanca Spain
National Research Center for Haematology Moscow Russia
Zobrazit více v PubMed
LeBlanc MR, Hirschey R, Leak Bryant A, LeBlanc TW, Smith SK. How are patient-reported outcomes and symptoms being measured in adults with relapsed/refractory multiple myeloma? A systematic review. Qual Life Res. 2020;29(6):1419-1431. PubMed PMC
Engelhardt M, Ihorst G, Singh M, et al. . Real-world evaluation of health-related quality of life in patients with multiple myeloma from Germany. Clin Lymphoma Myeloma Leuk. 2021;21(2):e160-e175. PubMed
Richardson PG, Oriol A, Larocca A, et al. . Melflufen and dexamethasone in heavily pretreated relapsed and refractory multiple myeloma. J Clin Oncol. 2021;39(7):757-767. PubMed PMC
Schjesvold FH, Dimopoulos MA, Delimpasi S, et al. . Melflufen or pomalidomide plus dexamethasone for patients with multiple myeloma refractory to lenalidomide (OCEAN): a randomised, head-to-head, open-label, phase 3 study. Lancet Haematol. 2022;9(2):e98-e110. PubMed
Sonneveld P, Richardson PG, Ludwig H, et al. . Benefit versus risk assessment of melflufen and dexamethasone in relapsed/ refractory multiple myeloma: analyses from longer follow-up of the OCEAN and HORIZON studies. Clin Lymphoma Myeloma Leuk. 2023;23(9):P687-696. PubMed
Richardson PG, Bringhen S, Voorhees P, et al. . Melflufen plus dexamethasone in relapsed and refractory multiple myeloma (O-12-M1): a multicentre, international, open-label, phase 1-2 study. Lancet Haematol. 2020;7(5):e395-e407. PubMed
Larocca A, Leleu X, Touzeau C, et al. . Patient-reported outcomes in relapsed/refractory multiple myeloma treated with melflufen plus dexamethasone: analyses from the phase II HORIZON study. Br J Haematol. 2022;196(3):639-648. PubMed PMC
Song KW, Dimopoulos MA, Weisel KC, et al. . Health-related quality of life from the MM-003 trial of pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone in relapsed and/or refractory multiple myeloma. Haematologica. 2015;100(2):e63-67. PubMed PMC
Fayers PM, Aaronson NK, Bjordal K, Groenvold M, Curran D, Bottomley A. on behalf of the EORTC Quality of Life Group. The EORTC QLQ-C30 Scoring Manual. 3rd ed. Brussels: European Organisation for Research and Treatment of Cancer, 2001. https://www.eortc.org/app/uploads/sites/2/2018/02/SCmanual.pdf. Accessed October 20, 2023.
Aaronson NK, Ahmedzai S, Bergman B, et al. . The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993;85(5):365-376. PubMed
EuroQol G. EuroQol--a new facility for the measurement of health-related quality of life. Health Policy. 1990;16(3):199-208. PubMed
Osoba D, Rodrigues G, Myles J, Zee B, Pater J. Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol. 1998;16(1):139-144. PubMed
Ojo AS, Araoye MO, Ali A, Sarma R. The impact of current therapeutic options on the health-related quality of life of patients with relapse/refractory multiple myeloma: a systematic review of clinical studies. J Cancer Surviv. 2024; 18: 673-697 PubMed
Terpos E, Dimopoulos MA, Boccadoro M, et al. . Health-related quality of life in patients with relapsed/refractory multiple myeloma treated with pomalidomide and dexamethasone +/-subcutaneous daratumumab: patient-reported outcomes from the APOLLO trial. Am J Hematol. 2022;97(4):481-490. PubMed
Popat R, Lonial S, Lee HC, et al. . DREAMM-2: belantamab mafodotin effect on disease symptoms and health-related quality of life in patients with relapsed/refractory multiple myeloma (RRMM). Presented at the European Hematology Association (EHA) Virtual Congress, 2020; Abstract EP1746. https://library.ehaweb.org/eha/2020/eha25th/294226/rakesh.popat.dreamm-2.belantamab.mafodotin.effect.on.disease.symptoms.and.html. Accessed October 18, 2023.
ClinicalTrials.gov
NCT03151811
